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Abstract
Background & Objective
Placental abruption, an ischemic placental disorder, complicates about 1 in 100 pregnan-
cies, and is an important cause of maternal and perinatal morbidity and mortality worldwide.
Metabolomics holds promise for improving the phenotyping, prediction and understanding
of pathophysiologic mechanisms of complex clinical disorders including abruption. We
sought to evaluate maternal early pregnancy pre-diagnostic serum metabolic profiles and
abnormal vaginal bleeding as predictors of abruption later in pregnancy.
Methods
Maternal serumwas collected in early pregnancy (mean 16 weeks, range 15 to 22 weeks)
from 51 abruption cases and 51 controls. Quantitative targeted metabolic profiles of serum
were acquired using electrospray ionization liquid chromatography-mass spectrometry (ESI-
LC-MS/MS) and the Absolute IDQ1 p180 kit. Maternal sociodemographic characteristics
and reproductive history were abstracted frommedical records. Stepwise logistic regression
models were developed to evaluate the extent to which metabolites aid in the prediction of
abruption. We evaluated the predictive performance of the set of selected metabolites using a
receiver operating characteristics (ROC) curve analysis and area under the curve (AUC).
Results
Early pregnancy vaginal bleeding, dodecanoylcarnitine/dodecenoylcarnitine (C12 / C12:1),
and phosphatidylcholine acyl-alkyl C 38:1 (PC ae C38:1) strongly predict abruption risk.
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The AUC for these metabolites alone was 0.68, for early pregnancy vaginal bleeding alone
was 0.65, and combined the AUC improved to 0.75 with the addition of quantitative metabo-
lite data (P = 0.003).
Conclusion
Metabolomic profiles of early pregnancy maternal serum samples in addition to the clinical
symptom, vaginal bleeding, may serve as important markers for the prediction of abruption.
Larger studies are necessary to corroborate and validate these findings in other cohorts.
Introduction
Placental abruption, the premature separation of the placenta from the uterus before delivery
of the fetus, is a life threatening obstetrical event that complicates approximately 1% of preg-
nancies [1]. Abruption occurs more frequently among women with multifetal gestation, coagu-
lopathies, acquired and heritable forms of thrombophilia, uterine anomalies, abdominal
trauma, hypertension, premature rupture of membranes, maternal-fetal hemorrhage, evidence
of mitochondrial dysfunction, oxidative stress, and intrauterine infections [2–8]. Other risk
factors for abruption include advanced maternal age, grand-multiparity, maternal cigarette
smoking and iron deficiency anemia during pregnancy [4–6,9]. Pathophysiologic mechanisms
involved in abruption and related perinatal disorders (e.g., preterm delivery, preeclampsia, and
intrauterine growth restriction) include uteroplacental ischemia, under perfusion, chronic hyp-
oxia, and infarctions.
Investigators have explored a number of biomarkers related to the pathogenesis of abrup-
tion. These include maternal first or second trimester serum concentrations of alpha-fetopro-
tein, human chorionic gonadotropin, pregnancy associated plasma protein-A, CA 125,
placental growth factor, soluble fms-like tyrosine kinase 1, endoglin and homocysteine [3,10–
16]. Despite considerable effort, however, the etiology of abruption remains elusive. Further-
more, clinicians have little information to help support care decisions, particularly when
patients present with signs and symptoms (e.g., vaginal bleeding in early pregnancy) of this
potentially devastating complication.
Metabolomics, the systematic study of metabolites in tissues and biofluids, has emerged as a
promising research tool to aid in building clinically relevant risk prediction models for disease
classification and progression. In perinatal medicine, investigators have reported findings illus-
trating the promise that metabolomics holds in establishing detailed phenotypes of complex
perinatal outcomes such as preterm delivery, fetal growth restriction preeclampsia, and gesta-
tional diabetes mellitus [17–20]. To our knowledge, no one has evaluated the extent to which
metabolites measured in maternal pre-diagnostic (early pregnancy) biofluids differentiate
women destined to develop abruption compared with those spared the disorder. To fill this
important gap in the literature, we designed a case-control study, nested within a prospective
cohort of pregnant women who provided serum samples in early pregnancy.
Specifically, we sought to establish the metabolic profiles of maternal sera from women with
pregnancies complicated by abruption and a control group of women without abruption using
targeted metabolomics methods. Our study has proposed biomarkers that, when validated in a
larger cohort, may serve to identify women at risk for abruption, and may provide new clues to
understand the pathogenesis of this devastating obstetrical complication.
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Material and Methods
Study Cohort and Setting
A cohort of 4,009 pregnant women providing a second trimester serum sample to a central lab-
oratory between 1994 and 1998, and who later delivered at Swedish Medical Center, WA con-
stitute the base cohort population in which the present case-control study is nested. This study
was part of the First and Second Trimester [9,21]. Each blood sample, collected at 15–22 weeks
gestation (mean ± standard deviation (SD): 16 ± 1.6 weeks) was centrifuged, and serum was
separated and stored at -20°C for 1 month. The serum was used to perform routine biochemi-
cal analyses as part of a second-trimester screening protocol for detecting pregnancies compli-
cated by neural tube defects and Down’s syndrome [21]. Serum remaining after routine testing
was transferred to the Center for Perinatal Studies at Swedish Medical Center and stored at
-80°C. Aliquots were shipped to the National Institutes of Health funded Eastern Regional
Comprehensive Metabolomics Resource Core at RTI International. All participants provided
signed informed consent to use their medical records and blood samples left over after clinical
tests were completed. This study was approved by the Institutional Review Board of Swedish
Medical Center, WA.
Placental abruption cases and controls
For this nested-case control study, we identified 51 women with clinically confirmed diagno-
sis of abruption for inclusion in the case group. For the purpose of the present study, we iden-
tified abruption cases through a careful review of medical records. We used medical records
to identify patients with a clinical diagnosis of abruption and determine whether the diagno-
sis could be objectively supported by evidence of pathological characteristics, signs and
symptoms of abruption. For the research diagnosis of abruption, using data abstracted from
medical records, we required evidence of blood clot behind the placenta (specifically indi-
cated in the delivery or pathology notes) accompanied by at least two of the following signs
and symptoms: (i) vaginal bleeding in late pregnancy that was not associated with placenta
previa or cervical lesions; (ii) uterine tenderness and/or abdominal pain; and (iii) fetal dis-
tress or death.
Women were eligible for inclusion in the study as controls if they had no clinical diagnosis
of abruption in their medical records. We randomly selected 51 women who had no vaginal
bleeding after 20 weeks gestation and who did not receive an abruption diagnosis. We
abstracted data from medical records for all abruption cases and controls to ensure that
antepartum and intrapartum medical histories are consistent with the presence (cases) or
absence (controls) of abruption. All participants delivered singleton infants and none had
an antepartum diagnosis of neural tube defect, Down’s syndrome or major congenital
malformation.
Data on sociodemographic characteristics, reproductive and medical history, antenatal care
and life-style characteristics were abstracted from medical records. Maternal abnormal early
pregnancy vaginal bleeding (i.e., vaginal bleeding in the first or second trimester) was deter-
mined based on physician report indicated in maternal medical records (yes/no). Information
about labor and delivery and infant outcomes was also collected from medical records. Con-
founding variables considered for adjustment included maternal age (<20, 20–34,35 years),
self-reported race/ethnicity (non-Hispanic White, African-American, Other), Medicaid pay-
ment status (yes/no), smoking during the index pregnancy (yes/no), chronic hypertension
(yes/no), preeclampsia (yes/no), preterm delivery (<37 weeks), birthweight (<2500 g) (yes/no)
and maternal pre-pregnancy body mass index (BMI).
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Metabolomics assays
Targeted metabolomics was conducted using electrospray ionization liquid chromatography–
mass spectrometry (ESI-LC-MS/MS) and MS/MS and the AbsoluteIDQ1 p180 kit (Biocrates
Life Sciences AG, Innsbruck, Austria). This kit allowed for the simultaneous quantification of
up to 188 metabolites, including free carnitine, 40 acylcarnitines (Cx:y), 21 amino acids (19
proteinogenic amino acids, citrulline and ornithine), 21 biogenic amines, hexose (sum of hex-
oses–about 90–95% glucose), 90 glycerophospholipids (14 lysophosphatidylcholines (lysoPC)
and 76 phosphatidylcholines (PC diacyl (aa) and acyl-alkyl (ae)), and 15 sphingolipids (SMx:
y). The assay details and the metabolite nomenclature for AbsoluteIDQ1 p180 kit and have
been previously described.[22] The stable labeled internal standard mixture and 10 μL of
serum was applied directly to the sample well. Samples were derivatized and extracted in prepa-
ration for analysis. Mass spectrometric (MS) analyses were carried out on an API 4000 LC-MS/
MS System (AB Sciex, Framingham, MA) equipped with an 1100 Series HPLC (Agilent Tech-
nologies, Palo Alto, CA) using an Agilent Eclipse XDB-C18 (3.5 μm) 3.0x100 mm column con-
trolled by Analyst 1.6.2 software. A unique multiple reaction monitoring (MRM) pair, specific
for each analyte, was used to measure the analytes and their stable labeled internal standard.
The internal standard was used for absolute and/or relative quantification. All data were pro-
cessed using a combination of Analyst 1.6.2 (AB Sciex LP, Ontario, Canada) and MetIDQ (Bio-
crates Life Sciences AG, Innsbruck, Austria) software.
Performance of quality control (QC) samples within an analytical run as well as pre- and
post-analysis system suitability checks were assessed. QC measures include reviewing quality
of each run, stability of internal standards signal, and drifts in retention time of standards. All
laboratory analyses were completed without knowledge of participants’ case or control status.
All raw and processed analytical data and associated de-identified metadata have been
uploaded to the public accessible NIH Common Fund Metabolomics Data Repository (www.
metabolomicsworkbench.org, Study ID#: ST000405).
Statistical analysis
We used logistic regression modeling to evaluate the extent to which metabolites, both in isola-
tion and combined with early pregnancy vaginal bleeding improves the prediction of abrup-
tion. Model selection was performed using stepwise logistic regression procedures (criteria:
model entry P<0.1 and model removal P>0.2), continuous variables were centered, and the
ratio of dodecanoylcarnitine/dodecenoylcarnitine (C12 / C12:1) was dichotomized at 1.2
(median value) and the final model was assessed for adequacy based on the Hosmer-Lemeshow
goodness-of-fit test. Finally, we used the receiver operating characteristics (ROC) curve and
the area under the curve (AUC) analysis to evaluate early pregnancy vaginal bleeding and
metabolites as predictors of abruption. Statistical tests for metabolomics data were conducted
using either a two-sided t-test with the Satterthwaite correction for unequal variances or the
chi-square test. Statistical analyses for metabolomics data were conducted using SAS 9.4 (SAS
Institute Inc., Cary, NC).
Results
Maternal socio-demographic and clinical characteristics of abruption cases and controls are
presented in Table 1. Cases and controls were similar as regards most maternal characteristics.
Newborns delivered of women with abruption were more likely to be low birthweight and to be
delivered preterm.
Quantitative analyses of the 188 endogenous metabolites included in The AbsoluteIDQ1
p180 kit (Biocrates Life Sciences AG, Innsbruck, Austria) indicated that 9 metabolites
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differentiated abruption cases as compared with controls. These metabolites included acylcar-
nitines, amino acids, amines, and glycerophopholipids (Table 2). Stepwise logistic regression
modeling was used to identify metabolites associated with the occurrence of abruption. Candi-
date predictors were early pregnancy vaginal bleeding (yes/no) that was associated with abrup-
tion (P = 0.002), as well as compounds or custom ratios from the Biocrates analysis (P<0.05).
Based on these model parameters, early pregnancy vaginal bleeding, dodecanoylcarnitine/
dodecenoylcarnitine (C12 / C12:1), and phosphatidylcholine acyl-alkyl C 38:1 (PC ae C38:1)
were selected, and the model fit the data with a Hosmer-Lemeshow goodness of fit of P = 0.17.
The odds ratios determined by the stepwise logistic regression model are shown in Fig 1. The
odds of abruption is increased with an increase in dodecanoylcarnitine/dodecenoylcarnitine
(C12 / C12:1), and a decrease in phosphatidylcholine acyl-alkyl C 38:1 (PC ae C38:1).
Table 1. Characteristics of Study Participants.
Abruption cases Controls P-value***
(N = 51) (N = 51)
n (%) n (%)
Gestational Age at blood collection 16.2 ± 1.6* 16.1 ± 1.6 0.95
Maternal age (years) 30.9 ± 5.5* 31.0 ± 5.5 0.91
Maternal age (years)
<20 2 (3.9) 1 (2.0) 0.63
20–34 33 (64.7) 37 (72.5)
35 16 (31.4) 13 (25.5)
Race
Non-Hispanic White 31 (60.8) 41 (80.4) 0.12
African American 4 (7.8) 2 (3.9)
Other 14 (27.5) 8 (15.7)
Unknown 2 (3.9) 0 (0.0)
Payment
Insurance or private 38 (74.5) 36 (70.6) 0.79
Medicaid 9 (17.7) 12 (23.5)
Unknown 4 (7.8) 3 (5.9)
Nulliparous 23 (45.1) 22 (43.1) 0.99
Unmarried 11 (21.6) 9 (17.7) 0.62
Cigarette smoker during pregnancy 6 (11.8) 4 (7.8) 0.62
Alcohol consumed during pregnancy 7 (13.7) 11 (21.6) 0.44
Pre-pregnancy Body Mass Index (kg/m2) 24.0 ± 5.8* 24.0 ± 6.0 0.99
Vaginal bleeding in early pregnancy 18 (36.7) 5 (10.2) 0.02
Chronic hypertension 4 (7.0) 2 (3.9) 0.68
Preeclampsia 2 (100.0) 0(0.0) —
Gestational age at delivery (weeks) 34.6 ± 5.1* 38.8 ± 2.0 <0.01
Preterm delivery (<37 weeks) 29 (56.9) 7 (13.7) <0.01
Preterm PROM** 10 (19.6) 4 (7.8) 0.084
Male infant gender 31 (60.8) 26 (51.0) 0.32
Infant weight (grams) 2519 ± 1035* 3405 ± 552 <0.01
Low birth weight (<2500 g) 21 9 (41.2) 2 (3.9) <0.01
*Mean ± SD (standard deviation)
** Premature rupture of membranes (PROM)
***P-value for Student’s t test or Chi-Square/Fisher’s Exact test)
doi:10.1371/journal.pone.0156755.t001
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We next assessed the extent to which maternal history of early pregnancy vaginal bleeding
alone and combined with metabolomics data are predictive of later abruption. As shown in Fig
2 and Table 3, the AUC for early pregnancy vaginal bleeding alone was 0.63 (95% CI 0.55,
0.71). The AUC for the model with only the metabolite data was 0.68 (95% CI 0.58, 0.79) (not
shown). Notably the AUC for bleeding combined with the quantitative metabolite biomarkers
improved to 0.76 (95% CI 0.66, 0.85) (P for model differences = 0.003). The predicted probabil-
ities for the abruption model including early pregnancy vaginal bleeding and metabolite data
Table 2. Metabolites that significantly differentiated placental abruption cases and controls via quantitative targeted analyses.
Metabolite Limit of Detection Abruption cases Controls Fold *
Classiﬁcation Analyte (LOD) (N = 51) (N = 51) change P-value**
Mean ± SD Mean ± SD
Acylcarnitines C16-OH 0.016 0.015 ± 0.0038 0.017 ± 0.0042 -1.12 0.021
Amino Acids Arg† 1.64 197.63 ± 71.55 233.84 ± 90.99 -1.18 0.029
Biogenic Amines Histamine 1.04 0.37 ± 0.01 0.37 ± 0.01 +1.01 0.034
Custom Ratios*** C12 / C12:1 C12 LOD: 0.09 1.16 ± 0.19 1.09 ± 0.19 +1.07 0.045
C12:1 LOD: 0.066
Glycerophospholipids PC ae C38:1 0.033 5.71 ± 1.61 6.63 ± 2.29 -1.16 0.021
Glycerophospholipids PC aa C40:1 0.472 0.56 ± 0.16 0.64 ± 0.22 -1.14 0.038
Glycerophospholipids PC aa C36:0 0.273 1.91 ± 0.78 2.33 ± 1.18 -1.22 0.040
Glycerophospholipids lysoPC a C18:1 0.183 15.54 ± 7.76 18.96 ± 8.76 -1.22 0.040
Glycerophospholipids PC aa C38:0 0.047 2.03 ± 0.71 2.34 ± 0.84 -1.15 0.048
Custom Ratios*** High C12/C12:1 C12 LOD: 0.09 25 (49.02%)†† 14 (27.45%)†† — 0.025
Low C12/C12:1 C12:1 LOD: 0.066 26 (50.98%)†† 37 (72.55%)†† —
High C12/C12:1 = C12 / C12:1 > 1.2; Low C12/C12 = C12:1  1.2
*Fold change (placental abruption case/control)
**p-values based on Student t tests with Satterthwaite approximation for continuous variables and chi-square test for categorical variables
***Ratio of dodecanoylcarnitine/dodecenoylcarnitine (C12 / C12:1)
†n = 50
††Cell count (%)
doi:10.1371/journal.pone.0156755.t002
Fig 1. The odds ratio of placental abruption determined by a stepwise logistic regression model for
metabolites associated with the occurrence of placental abruption andmaternal history of abnormal
early pregnancy vaginal bleeding.
doi:10.1371/journal.pone.0156755.g001
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are shown in the right panel of Fig 2. Consistent with the Fig 1, the probability of abruption is
increased with the presence of vaginal bleeding and an increase in dodecanoylcarnitine/dode-
cenoylcarnitine (C12 / C12:1), and a decrease in phosphatidylcholine acyl-alkyl C 38:1 (PC ae
C38:1). Furthermore, as a planned sub-group analysis, we examined the correlation between
the identified metabolite markers and vaginal bleeding. In this analysis there are no associa-
tions between early vaginal bleeding and the metabolite markers used in the placental abrup-
tion model.
Discussion
We identified metabolic differences between women predestined to develop abruption as com-
pared to those whose pregnancies were not complicated by the disorder. Specifically, we identi-
fied alterations of fatty acid oxidation and phospholipid metabolism that may reflect
abnormalities prior to the clinical presentation of abruption. Using quantitative metabolomics
methods, we found that a sub-group of maternal serum metabolites (i.e., dodecanoylcarnitine/
dodecenoylcarnitine (C12 / C12:1), and phosphatidylcholine acyl-alkyl C 38:1 (PC ae C38:1) to
be as predictive as the current clinical symptom of early pregnancy vaginal bleeding, and that
the predictive probability of abruption was increased by using both the clinical symptom of
vaginal bleeding and the metabolite biomarkers. The AUC for these metabolites alone was
0.68, for early pregnancy vaginal bleeding alone was 0.63, and combined the ACU significantly
improved to 0.75 with the addition of quantitative metabolite data (P = 0.003).
Acylcarnitines, involved in organic acid metabolism, belong to a group of markers for mito-
chondrial function and reflect metabolic processes involved in long-chain fatty acid metabo-
lism and related mitochondrial function [23]. They are synthesized by the enzyme carnitine
palmitoyltransferase 1 (CPT 1) that is known to be responsible for the transport of fatty acids
Fig 2. Receiver operating characteristic (ROC) curves for placental abruption prediction using (a) early pregnancy vaginal bleeding, (b)
metabolites and early pregnancy vaginal bleeding, and (c) predicted probabilities for placental abruption.
doi:10.1371/journal.pone.0156755.g002
Table 3. Area under the curve (AUC) of receiver operating characteristic (ROC) curves for placental abruption prediction.
Area Under the ROC Curve Model AUC Compared to VB Error Rate
(95% CI) Model AUC
Model
Vaginal Bleeding Only 0.63 (0.55, 0.71) — 0.37
Metabolites Only 0.68 (0.58, 0.79) P = 0.480 0.36
Vaginal Bleeding + Metabolites 0.76 (0.66, 0.85) P = 0.003 0.29
doi:10.1371/journal.pone.0156755.t003
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into the mitochondrial matrix.[24] Our analysis revealed significant differences in the concen-
trations of the acylcarnitine, dodecanoylcarnitine, which is present in fatty acid oxidation dis-
orders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I
deficiency, and carnitine palmitoyltransferase II deficiency.
Incomplete fatty acid oxidation results in elevated acylcarnitine concentrations [25], which
is used in newborn screening to detect metabolic disorders.[26] Furthermore, alterations in
concentrations of certain acylcarnitines have been documented in women with gestational dia-
betes mellitus [27] and in women with hypertensive disorders of pregnancy [28]. On balance,
our observations are consistent with an emerging literature suggesting impaired mitochondrial
function in the pathogenesis of abruption.
Available evidence suggests that impaired mitochondrial function may play a significant
role in the complex pathogenesis of abruption [7,8,29,30]. In a pilot study of 233 abruption
cases and 238 controls, Williams and colleagues [7] reported an increased odds of abruption
with elevated mitochondrial DNA density (a biomarker of systemic mitochondrial dysfunction
and oxidative stress) and that the association was particularly elevated among women with a
concomitant diagnosis of preeclampsia and abruption. Namely, women with elevated mtDNA
copy number and those with a diagnosis of preeclampsia had a 6.7-fold (95% CI 2.6–17.2)
increased odds of abruption as compared with normotensive women without elevated mtDNA
copy number. In addition, Qiu and colleagues[8] recently provided preliminary evidence for
associations of target tissue-specific mitochondrial dysfunction with the risk abruption. Briefly,
the authors reported that the odds of abruption was elevated among women who delivered pla-
centas with higher mtDNA density (120.5, the median) as compared with those with lower
values (<120.5) (OR = 2.4, 95% CI 1.1–5.1). These data are corroborated by findings from can-
didate gene studies that document elevated risks of abruption among women with variations in
mitochondrial and oxidative phosphorylation related genes [29,30]. Our study showed that the
odds of abruption increased with an increase in C12 / C12:1 and a decrease in PC ae C38:1.
These related pathways (acylcarnitine or phosphaticholine) branch at the metabolite diacylgly-
cerol [31]. Diacylglycerol is transformed to the endocannabinoid 2-arachidononylglycerol
(2-AG), and 2-AG is converted to prostogladin glycerol esters. Recently Vaswani et al. [32]
demonstrated that the enzyme prostaglandin-endoperoxide synthase-2 (PTGS-2), which con-
verts 2-AG to prostaglandin glycerol esters, is down-regulated in the placenta, consistent with
studies investigating the importance of PTGS-2 in preterm labor. These observations suggest
that PTSGS-2 may play a role in the pathogenesis of abruption.
Several methodological strengths must be considered when interpreting the results of our
study. First, our study provided preliminarily evidence for temporal relationship between
maternal early pregnancy metabolomics profile and abruption risk later in pregnancy. Specifi-
cally, we documented alterations in maternal early pregnancy serum metabolomics profile (in
samples collected 16 weeks gestation on average) several months before the condition was diag-
nosed clinically. Second, we were able to identify metabolites with both small and large case-
control differences that are predictive of abruption. Third, in this initial study, we were able to
combine clinical and quantitative metabolomics data to develop a clinical risk prediction
model, which if confirmed in an independent sample, may have clinical utility. However, the
small sample size our study hindered our capacity to formally assess statistical interactions of
maternal characteristics (other than early pregnancy vaginal bleeding) and alteration in the
early pregnancy serum metabolome on abruption risk. In a larger sample, we propose that
investigation of statistical interactions of maternal metabolomics profile with other clinical
characteristics such as maternal race/ethnicity, nutritional status and dietary intake, pre-preg-
nancy obesity, diabetes and hypertensive disorders may be informative. Our review of the avail-
able literature suggest that systematic evaluations of organic acid metabolites in relation to
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individual obesity status may be of etiologic importance. Future studies, with large sample sizes
that allow for serial longitudinal measures of maternal serum metabolome across the trimesters
of pregnancy are needed to further clarify the temporal relationship of specific organic acid
metabolites and the incidence of abruption. Although we controlled for confounding, it cannot
be concluded with certainty that the reported associations are unaffected by residual confound-
ing. Of particular concern was the absence of detailed information about maternal use of illicit
drugs during pregnancy, a previously identified placental abruption risk factor [4,33]. Finally,
the stability of the metabolites after a long period of storage merits consideration. As part of
the European project EnviroGenomarkers Hebels et al [34] studied the feasibility of using
blood samples that had been stored in biobanks at -80°C for 4–19 years. Notably, the authors
found that the long-term storage did not significantly affect the metabolomics analysis. Fur-
thermore, we note that important scientific contributions have been made from metabolomics
studies of archived samples including the Framingham Heart Study [35], the CARET study
repository [36], and the Malmo Diet and Cancer Cardiovascular Cohort [37].
In summary, in this case-control metabolomics study of maternal early pregnancy serum
samples, we identified fatty acids involved in organic acid metabolism, and choline-containing
phospholipids, as well as a number of other compounds to be associated with the risk of inci-
dent abruption. Some of these candidate metabolites point towards a role of impaired mito-
chondrial function, and alterations in phospholipid and lipoprotein metabolism in abruption
pathophysiology. We showed that several endogenous metabolites including long-chain acyl-
carnitines and phospholipids, in particular dodecanoylcarnitine, dodecenoylcarnitine and
phosphatidylcholine acyl-alkyl C 38:1 are associated with incident abruption and that these
metabolites, together with a clinical history of early pregnancy vaginal bleeding increase the
predictive probability of the disorders. Future studies are warranted to further identify bio-
markers of abruption and to elucidate the biological mechanisms of this important complica-
tion of pregnancy.
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